Bone-Mimicking Injectable Gelatine/Hydroxyapatite Hydrogels

[EN] Bioactive synthetic hydrogels have emerged as promising materials because they can provide molecularly tailored biofunctions and adjustable mechanical properties. To mimic the mineralogical and organic components of the natural bone, hydroxyapatite and a tyramine conjugate of gelatine were combined in this study. The effect of various amounts of in situ synthesized hydroxyapatite in gelatine-tyramine on the morphology and physical properties of injectable hydrogels was investigated. Mineralogical identification confirmed successful precipitation of in situ formed hydrox yapatite. Better distribution of hydroxyapatite crystal agglomerates within modified gelatine was found at 5 % of hydroxyapatite, which could be responsible for increased storage modulus with respect to pure gelatine hydrogel. Prepared composite hydrogels are non-toxic and support the proliferation of Hek293 cells.The authors are grateful for the financial support of the Spanish Ministry of Economy and Competitiveness through the MAT2016-76039-C4-1-R project (including Feder funds) and the Croatian Science Foundation under the project IP-2014-09-3752.Rogina, A.; Sandrk, N.; Teruel Biosca, L.; Antunovic, M.; Ivankovic, M.; Gallego Ferrer, G. (2019). Bone-Mimicking Injectable Gelatine/Hydroxyapatite Hydrogels. Chemical and Biochemical Engineering Quarterly Journal. 33(3):325-335. https://doi.org/10.15255/CABEQ.2019.1663S32533533

International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia - data from the I-CAH registry.

OBJECTIVE: Despite published guidelines no unified approach to hormone replacement in congenital adrenal hyperplasia (CAH) exists. We aimed to explore geographical and temporal variations in the treatment with glucocorticoids and mineralocorticoids in CAH. DESIGN: This retrospective multi-center study, including 31 centers (16 countries), analyzed data from the International-CAH Registry. METHODS: Data was collected from 461 patients aged 0-18 years with classic 21-hydroxylase deficiency (54.9% females) under follow-up between 1982 - 2018. Type, dose and timing of glucocorticoid and mineralocorticoid replacement was analyzed from 4174 patient visits. RESULTS: The most frequently used glucocorticoid was hydrocortisone (87.6%). Overall, there were significant differences between age groups with regards to daily hydrocortisone-equivalent dose for body surface, with the lowest dose (median with interquartile range) of 12.0 (10.0 - 14.5) mg/ m2/ day at age 1 - 8 years and the highest dose of 14.0 (11.6 - 17.4) mg/ m2/ day at age 12-18 years. Glucocorticoid doses decreased after 2010 in patients 0-8 years (p<0.001) and remained unchanged in patients aged 8-18 years. Fludrocortisone was used in 92% of patients, with relative doses decreasing with age. A wide variation was observed among countries with regards to all aspects of steroid hormone replacement. CONCLUSIONS: Data from the I-CAH Registry suggests international variations in hormone replacement therapy, with a tendency to treatment with high doses in children